The US Oncology Network in The News

« Back to News

US Oncology Research Announces Schedule of Presentations at the 2016 American Society of Hematology Annual Meeting and Exposition

Sixteen presentations on clinical research conducted by top US Oncology Research affiliated investigators will take place at ASH 2016

The Woodlands, Texas (November 30, 2016) — More than 20 leading investigators affiliated with US Oncology Research participated in sixteen studies that will be presented at the 58th American Society of Hematology Annual Meeting and Exposition (ASH), a premier scientific event in malignant and non-malignant hematology, held December 3-6 in San Diego. Six oral and ten poster presentations co-authored by US Oncology Research affiliated investigators cover topics such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma, small lymphocytic leukemia, and mantle cell lymphoma.

David Andorsky, MD, oncologist and hematologist with Rocky Mountain Cancer Centers, an affiliate of US Oncology Research, will be presenting results from a lymphoma study titled, “MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma.” The poster presentation will take place Saturday, December 3 from 5:30 to 7:30pm PT in Hall GH.

“This is an important study for patients being treated for indolent B-cell lymphoma,” said Dr. Andorsky. “R2 induction therapy shows favorable activity and a good safety profile for many patients. This is a preliminary report, and further follow up will be needed to demonstrate the efficacy and safety of this regimen.”

Jeff Sharman, MD, director of Research at Willamette Valley Cancer Institute and Research Center and medical director of Hematology Research for The US Oncology Network, will be presenting results from a mantle cell lymphoma study titled, “Results of a Phase 2 Trial Evaluating Efficacy and Safety of Entospletinib (GS-9973) in Patients with Mantle Cell Lymphoma.” The poster presentation will take place Sunday, December 4 from 6:00 to 8:00pm PT in Hall GH.

“Research for hematologic malignancies in the community setting is crucial for the advancement of cancer treatment,” said Dr. Sharman. “I’m excited about the results being presented this year and hope it will lead to additional treatment options for patients.”

Also among the findings co-authored by investigators affiliated with US Oncology Research is the ongoing Phase 2 study of Brentuximab Vedotim with Rchp as frontline therapy in patients with High-Intermediate/High-Risk DLBCL. Results of the trial, co-authored in part by 11 US Oncology Research affiliated physicians, will be featured as an oral presentation on Saturday, December 3 at 9:45am PT in Room 7AB.

“It’s outstanding to see the cutting-edge research conducted by physicians affiliated with US Oncology Research each and every year,” said Michael Seiden, MD, chief medical officer, The US Oncology Network and McKesson Specialty Health. “The patient is top priority for these physicians, which is evidenced by the quality and caliber of their work and the level of their dedication. Research is the cornerstone of advancing treatment, and the physicians presenting at this year’s ASH are leading the way.”

The full schedule of US Oncology Research affiliated data presentations, including location information, can be found here. For more information or to interview a trial investigator, contact Claire Crye at 281-825-9927 or or Kerry Sinclair at 323-602-1096 or

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and nearly 160 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled more than 64,000 patients in more than 1,500 trials since inception in 1992 and have played a role in more than 60 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information visit

Media Contacts
Claire Crye
US Oncology Research

Kerry Sinclair
GCI Health on behalf of US Oncology Research